ClinicalTrials.gg
RecruitingNCT05681572pediaPREMUpdated Jul 17, 2026

Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia

A Phase 3 interventional study of Midazolam and Dexmedetomidine in Anesthesia, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University Hospital, Montpellier · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
7 Years to 18 Years
Sex
All
01

Study summary

Children undergoing general anesthesia for surgery commonly need sedative and anxiolytic premedication but little clinical evidence supports is benefit for children older than 7 years old.

The aim of this prospective randomized clinical trial is to assess the impact of pharmacologic premedication on perioperative children experience.

Read the detailed description

Surgery is a stressful experience in children with preoperative and postoperative anxiety.

For preschooler undergoing surgery, anxiety is the highest in the preoperative period.

Most of studies have been conducted on young children (\< 7yrs old) to show the relationship between preoperative anxiety and emergence of delirium and postoperative maladaptive behavioral changes.

Sedative and anxiolytic medication is frequently used in children to reduce anxiety and postoperative maladaptive experiences. Nevertheless, little clinical evidence supports is benefit for children older than 7 years.

Treating anxiety is not necessarily associated with better experience in all children because premedication causes postoperative sedation, amnesia and cognitive impairment.

The aim of this prospective randomized clinical trial is to assess the impact of pharmacologic premedication on perioperative children experience using self-report questionnaire.

Patients are randomized to 2 groups to received pharmacologic premedication or placebo.

For the premedication group, children are randomly allocated to be premedicated with either with the midazolam or dexmedetomidine

02

Conditions studied

  • Anesthesia

Browse trials for

Keywords

  • children premedication
  • anesthesia
  • children perioperative experience
  • anxiety
  • sedation
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject over 7 and under 18 years of age
  • Subjects who are scheduled for surgery
  • Subject who will be under general anesthesia
  • Subject able to complete a self-questionnaire in French

Exclusion criteria

Exclusion Criteria:

  • Subject who has already participated in the pediaPREM study
  • Subject with a treated anxiety disorder
  • Subject with cognitive disorders
  • Subject suffering from chronic pain (outside the operated area)
  • Subject with ADD (Attention Deficit Disorder) with or without hyperactivity, with or without treatment
  • Subject suffering from mental retardation
  • Subjects receiving psychotropic treatment
  • Subject whose intervention could reduce the ability to complete a self-questionnaire (neurosurgery etc.)
  • Subject with a to midazolam and its
  • Subject with a contra-indication to dexmedetomidine and its excipients
  • Subjects who need to receive intravenous alpha agonist in perioperative
  • Subjects requiring emergency intervention
  • Subjects requiring preoperative hypnosis
  • Subject who needs general anesthesia for diagnostic purposes (, etc...)
  • Subject having had a surgical intervention in the month preceding the inclusion.
  • Subject who will have an iterative surgical intervention within 15 days (removal of material, burns etc...)
  • Subjects who are scheduled for surgery as part of oncology management
  • Pregnant or breastfeeding woman
  • Subject whose two parents have not signed a written
  • Subjects who are not affiliated with or benefiting from a social security plan
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Premedication Group (Midazolam)

    Midazolam (0,5 mg/kg; max 10 mg), oral administration, 45 minutes prior entering in the operating room

    Drug: Midazolam

  • Experimental
    Premedication Group (Dexmedetomidine)

    Dexmedetomidine (2 µg/kg), oral administration, 45 minutes prior entering in the operating room

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo Group

    grenadine syrup (3 mL), oral administration, 45 minutes prior entering in the operating room

    Drug: Placebo

Interventions

  • 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.

  • 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.

  • DrugPlacebo

    45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.

06

What researchers measure

Primary outcomes

  1. EVANpedia Score

    To evaluate patient experience of the perioperative and post-operative period

    Time frame: from the day of surgery up to the day one after surgery

Secondary outcomes

  1. VAS-anxiety Scores

    To evaluate the perioperative level of anxiety thanks to the Visual Analogue Scale (VAS)

    Time frame: from preoperative period up to 6 postoperative month

  2. Postoperative waking delay

    Time to wake up after surgery (minutes) to evaluate the delay emergence from anesthesia

    Time frame: from the end of the surgery up to the exit of the recovery room

  3. Modified Brice questionnaire Score

    To evaluate postoperative amnesia after anesthesia

    Time frame: from the day of surgery up to 1 day

  4. Post Hospitalization Behavior Scores

    To evaluate changes of behavioral (appetite, sleep, sociability) after surgery

    Time frame: 15 postoperative days

  5. quality of life

    to evaluate the impact of the perioperative experience on the long-term experience

    Time frame: 6 postoperative months

  6. neuropathic pain

    to evaluate the percentage of patients with long-term neuropathic pain

    Time frame: 6 postoperative month

  7. FPS-r scores

    To evaluate the Postoperative level of pain thanks to the Faces Pain Scale-revised (FPS-r)

    Time frame: from the end of the surgery up to 6 post-operative month

  8. Quality of life PedsQL

    The quality of life will be measured by PedsQL in order to evaluate the impact of the perioperative experience on the long-term experience. The 23 questions cover 4 different domains: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items) and academic functioning (5 items). The parent questionnaire assesses parents' perceptions of their child's health-related quality of life. On the PedsQL Generic Core Scales, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life).

    Time frame: Up to 6 months post-operatively

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2027, 54 months after the start.

Of 28 phase 3 interventional studies under Anxiety Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Jan 12, 2023
StartActual
Apr 18, 2023
Primary completionEst.
Oct 18, 2027
CompletionEst.
Oct 18, 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05681572
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Apr 18, 2023
Primary completion
Oct 18, 2027 (estimated)
Completion
Oct 18, 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Sophie BRINGUIER, PHD
Contact
s-bringuierbranchereau@chu-montpellier.fr
0467338661 ext. +33
Christophe DADURE, PHD
study director · Hospital of Montpellier

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Dexmedetomidine

Start the discussion